Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5 - Candlesense
ARCT Regulatory

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

(NASDAQ:ARCT) Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children

Related Questions

What competitive pressures or alternative treatments exist for pediatric plaque psoriasis, and how could they influence market share for ZORYVE®? What are the regulatory timelines and potential risks for FDA approval of the supplemental NDA, and how could this impact the stock volatility? How might the expanded pediatric indication for ZORYVE® affect Arcutis' revenue forecasts and earnings guidance?
Find similar articles on Candlesense globenewswire